Neurocrine Biosciences (BSP:N1BI34) Other Income (Expense) : R$-328 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Neurocrine Biosciences Other Income (Expense)?

Neurocrine Biosciences's other income expense for the Neurocrine Biosciences's pretax income for the three months ended in Dec. 2023 was R$240 Mil. Its other income expense for the trailing twelve months (TTM) ended in Dec. 2023 was R$-328 Mil.

Neurocrine Biosciences Other Income (Expense) Historical Data

The historical data trend for Neurocrine Biosciences's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurocrine Biosciences Other Income (Expense) Chart

Neurocrine Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Income (Expense)

Get a 7-Day Free Trial

-607.88

-967.20

-455.79

-146.87

-284.68

Neurocrine Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Income (Expense)	Get a 7-Day Free Trial															81.83	-687.01	240.26	-121.00	240.09

Neurocrine Biosciences Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was R$-328 Mil.

Neurocrine Biosciences (BSP:N1BI34) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Neurocrine Biosciences (BSP:N1BI34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (BSP:N1BI34) » Definitions » Other Income (Expense)

Comparable Companies

Traded in Other Exchanges

NBIX:USA NB3:Germany

Address

12780 El Camino Real, San Diego, CA, USA, 92130

Website

https://www.neurocrine.com

Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Neurocrine Biosciences (BSP:N1BI34) Headlines

No Headlines